Cardiotonic steroids differentially affect intracellular Na+ and [Na+]i/[K+]i-independent signaling in C7-MDCK cells

Olga A Akimova1, Alexei Y Bagrov, Olga D Lopina

  • 1Centre de recherche, Centre hospitalier de l'Université de Montréal, Montreal, Quebec H2W 1T7, Canada.

Insights

Cardiotonic steroids (CTS) show varied effects on cell survival. Marinobufagenin inhibits the Na+,K+-pump without causing cell death, unlike ouabain, revealing distinct signaling pathways.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Cardiotonic steroids (CTS) are known to inhibit the Na+,K+-pump.
  • Previous findings suggested ouabain induces cell death independently of Na+,K+-pump inhibition.
  • This raises the possibility of CTS with differential effects on pump activity and cell survival.

Purpose of the Study:

  • To compare the effects of various CTS on Na+,K+-pump activity, intracellular sodium ([Na+](i)) levels, and cell survival.
  • To investigate the mechanisms underlying CTS-induced cell death and signaling.

Main Methods:

  • Madin-Darby canine kidney cells were treated with different CTS (ouabain, bufadienolides, marinobufagenin).
  • Na+,K+-pump inhibition was assessed by measuring 86Rb influx.
  • Cell viability was evaluated using MTT assays and caspase-3 activation.
  • Intracellular sodium ([Na+](i)) content was measured.

Main Results:

  • Ouabain and other cardenolides/bufadienolides inhibited the Na+,K+-pump, decreased MTT staining, and induced significant cell death.
  • Marinobufagenin (MBG) inhibited the Na+,K+-pump and increased [Na+](i) but did not affect cell survival or MTT staining.
  • MBG suppressed ouabain-induced [Na+](i)/[K+](i)-independent signaling and cell death.

Conclusions:

  • CTS exhibit distinct potencies in inhibiting the Na+,K+-pump and triggering [Na+](i)/[K+](i)-independent signaling pathways.
  • Marinobufagenin represents a CTS that inhibits the Na+,K+-pump without inducing cell death, suggesting separable mechanisms of action.
  • These findings differentiate CTS based on their impact on cell survival and pump inhibition, offering potential for targeted therapeutic development.

Related Concept Videos

Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...